Viatris cuts price of TB drug by 34%

The decision to cut the price will help to expand access to a critical new treatment in more than 140 countries, including India, which has one of the highest TB burdens. The price reduction will bring both (BPaL and BPaLM closer to $500 per patient course.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/zM8wQ5S
via IFTTT